Cover Image

Comparison of E-test and Microbroth dilution Methods for Determining Voriconazole, Itraconazole and Amphotericin B MICs for Aspergillus fumigatus and Aspergillus flavus

VINOTHA S

Abstract


Background of the study Infections caused by filamentous fungi, especially Aspergillus fumigatus and  Aspergillus flavus are responsible for majority of infections in immunocompromised hosts. The Clinical Laboratory Standards Institute Subcommittee on Antifungal Susceptibility Tests has proposed a standard procedure for antifungal susceptibility  testing of molds (CLSI document M38-A2) . Although the  reference procedure for molds is essential for standardization of results, it is cumbersome and time-consuming other methods have been evaluated . Among these methods, Etest has been suggested as an alternative procedure for antifungal   susceptibility testing of molds. Hence the determination of invitro susceptibilities of Aspergillus isolates to the established and investigational methods are warranted .MaterialsMethods 64 isolates of clinically significant Aspergillus flavus(29) and   Aspergillus fumigatus (35) obtained from various clinical   samples were taken up for the study . Minimal inhibitory concentrations(MICs) for these isolates were determined by microbroth dilution method as per CLSI document M38-A2 and E-Test. The percentage of agreement between the E test and the reference microbroth dilution methods were   calculated. Results In this study we evaluated the in vitro          susceptibilities of 29 Aspergillus flavus isolates and 35  Aspergillus fumigatus isolates, to voriconazole, itraconazole, and amphotericin B by the E-test and CLSI M38-A2  microbrothdilution methods. An overall 100 percent agreement for voriconazole and itraconazole and 86 percent for  amphotericin B at 24 hrs and 97,93and 73 percentages  respectively at 48hrs was seen for Aspergillus flavus isolates. For Aspergillus fumigatus an overall agreement of voriconazole, itraconazole and amphotericin B was 97,91 and 97percentages respectively at 24 hrs and at 48hrs lower agreement of 71,77and 69 percentages were noted respectively. Greater discrepencies in MICs were noted at 48hours of incubation of   E-Test suggesting the importance of incubation time for the Etest. Conclusion The results of this investigation showed a good level of overall agreement between the E-test and   microbroth dilution methods . Our results suggest that the E test is suitable for routine use in susceptibility testing of Aspergillus spp. against amphotericin B and Triazoles.

 


Full Text:

PDF

References


M. C. Serrano1, M. Ramírez1, D. Morilla1, A. Valverde1, M. Chávez1, A. Espinel-Ingroff2, R. Claro,A. Fernández3, C. Almeida3 and E. Martín-Mazuelos1 A comparative study of the disc diffusion method with the brothmicrodilution and Etest methods for voriconazole susceptibility testing of Aspergillus spp.Journal of Antimicrobial Chemotherapy (2004) 53, 739–742

Ana Espinel-Ingroff1,2 and A. Rezusta E-Test Method for Testing Susceptibilities of Aspergillus spp to the New Triazoles Voriconazole and Posaconazole and to Established Antifungal Agents: Comparison with NCCLS Broth Microdilution Method .Journal of clinical microbiology, June 2002, p. 2101–2107

Iwen, P. C., M. E. Rupp, and S. H. Hinrichs. 1997. Invasive mold sinusitis: 17 cases in immunocompromised patients and review of literature. Clin. Infect. Dis. 24:1178–1184.

Adrien szekely, Elizabeth m. Johnson, and David w. Warnock Comparison of E-Test and Broth Microdilution Methods forAntifungal Drug Susceptibility Testing of Molds Journal of clinical microbiology,May 1999, p. 1480–1483

Denning, D. W. 1996. Therapeutic outcome in invasive aspergillosis. Clin. Infect. Dis. 23: 608–615.

Denning, D. W. 1998. Invasive aspergillosis. Clin. Infect. Dis. 26:781–805.

Espinel-Ingroff, A., M. Bartlett, V. Chaturvedi, M. A. Ghannoum, K. Hazen, M. A. Pfaller, M. G. Rinaldi, and T. J. Walsh. 2001. Optimal susceptibility testing conditions for detection of azole resistance in Aspergillus spp.: NCCLS collaborative evaluation. Antimicrob. Agents Chemother. 45:

–1835.

Verweij, P. E., M. F. Q. van den Bergh, P. M. Rath, B. E. de Pauw, A. Voss,and J. F. G. M. Meis. 1999. Invasive aspergillosis caused by Aspergillus ustus: case report and review. J. Clin. Microbiol. 37:1606–1609.

Denning, D. W., K. Venkateswarlu, K. L. Oakley, M. J. Anderson, N. J. Manning, D. A. Stevens, D. W. Warnock, and S. L. Kelly. 1997. Itraconazole resistance in Aspergillus fumigatus. Antimicrob. Agents Chemother. 41:1364– 1368.

Lortholary, O., M.-C. Meyohas, B. Dupont, J. Cadranel, D. Salmon-Ceron, D. Peyramond, D. Simonin, et al. 1993. Invasive aspergillosis in patients with acquired immunodeficiency syndrome: report of 33 cases. Am. J. Med. 95:177–187.

Patterson, T. F., W. R. Kirkpatrick, M. White, J. W. Hiemenz, J. R. Wingard, B. Dupont, M. G. Rinaldi, D. A. Stevens, and J. R. Graybill. 2000. Invasive aspergillosis: disease spectrum, treatment practices, and outcomes. Medicine 79:250–260.

CLSI (2008b) Reference method for broth dilution antifungal susceptibility testing of fi lamentous fungi; approved standard CLSI document M38-A2. Clinical and Laboratory Standards Institute, Wayne.

Anaissie, E. 1992. Opportunistic mycoses in the immunocompromised host:experience at a cancer center and review. Clin. Infect. Dis. 14(Suppl. 1):S43–S53.

Pfaller, M. A., S. A. Messer, A. Houston, K. Mills, and A. Bolmstrom. 2000. In vitro susceptibility testing of filamentous fungi: comparison of Etest and reference microdilution methods for determining itraconazole MICs. J. Clin.Microbiol. 38:3359–3361.

Barry A. L., M. A. Pfaller, S. D. Brown, A. Espinel-Ingroff, M. A. Ghannoum,C. Knapp, R. P. Rennie, J. H. Rex, and M. G. Rinaldi. 2000. Quality control limits for broth microdilution susceptibility tests of ten antifungal agents. J. Clin. Microbiol. 38:3457–3459.

Pfaller M. A., S. A. Messer, R. J. Hollis, R. N. Jones, and the Sentry Participants Group. 2002 Antifungal activities of posaconazole, ravuconazole and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrob. Chemother. 46:1032–1037.


Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.

An Initiative of The Tamil Nadu Dr M.G.R. Medical University